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Preclinical studies indicate autophagy inhibition with hydroxychloroquine (hCQ) can augment the efficacy of Dna-
damaging therapy. The primary objective of this trial was to determine the maximum tolerated dose (MTD) and efficacy 
of hCQ in combination with radiation therapy (RT) and temozolomide (TMZ) for newly diagnosed glioblastoma (GB). a 3 
+ 3 phase i trial design followed by a noncomparative phase ii study was conducted in GB patients after initial resection. 
Patients received hCQ (200 to 800 mg oral daily) with RT and concurrent and adjuvant TMZ. Quantitative electron micros-
copy and immunoblotting were used to assess changes in autophagic vacuoles (aVs) in peripheral blood mononuclear 
cells (PBMC). Population pharmacokinetic (PK) modeling enabled PK-pharmacodynamic correlations. sixteen phase i 
subjects were evaluable for dose-limiting toxicities. at 800 mg hCQ/d, 3/3 subjects experienced Grade 3 and 4 neutro-
penia and thrombocytopenia, 1 with sepsis. hCQ 600 mg/d was found to be the MTD in this combination. The phase ii 
cohort (n = 76) had a median survival of 15.6 mos with survival rates at 12, 18, and 24 mo of 70%, 36%, and 25%. PK analysis 
indicated dose-proportional exposure for hCQ. significant therapy-associated increases in aV and lC3-ii were observed 
in PBMC and correlated with higher hCQ exposure. These data establish that autophagy inhibition is achievable with 
hCQ, but dose-limiting toxicity prevented escalation to higher doses of hCQ. at hCQ 600 mg/d, autophagy inhibition was 
not consistently achieved in patients treated with this regimen, and no significant improvement in overall survival was 
observed. Therefore, a definitive test of the role of autophagy inhibition in the adjuvant setting for glioma patients awaits 
the development of lower-toxicity compounds that can achieve more consistent inhibition of autophagy than hCQ.
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Introduction
Concomitant radiation therapy with temozolomide followed 
by maintenance TMZ has been established as the standard of 
care for patients with newly diagnosed glioblastoma.1 Despite 
this advance, GB remains a uniformly lethal malignancy. 
Autophagy is a therapeutic target in cancer due to its ability to 
promote the survival of cancer cells in the face of metabolic and 
therapeutic stress.2 In glioma cells autophagy has been demon-
strated to be an adaptive response to both radiation and TMZ,3-7 
suggesting that inhibition of autophagy could have therapeutic 
benefit.
Chloroquine (CQ) and its derivative HCQ are able to inhibit 
autophagy. Chloroquine has been used for 60 y in humans for 
malaria prophylaxis and treatment, rheumatoid arthritis, and 
human immunodeficiency virus.8-10 It is an inexpensive orally 
available drug that has central nervous system penetration. In 
vitro studies indicated that higher concentrations of CQ deriva-
tives than traditionally used for malaria and rheumatic disorders 
may be necessary to effectively block tumor cell autophagy and 
elicit tumor cell death. HCQ has less cumulative retinal toxic-
ity11 and is likely safer to dose-escalate than CQ.2
We hypothesized that the addition of HCQ to standard 
chemoradiation and adjuvant chemotherapy would be safe, and 
evidence of autophagy inhibition and preliminary antitumor 
activity could be seen in adults with newly diagnosed GB. To 
test this hypothesis we designed a phase I/II clinical trial that 
incorporated a traditional phase I dose-escalation component, 
novel methods to assess the pharmacokinetic-pharmacodynamic 
(PK-PD) relationship for HCQ dose and autophagy inhibition, 
and assessment of overall survival in the phase II portion of the 
trial.
Results
Patient characteristics
A total of 92 patients (58 men) were enrolled between 
September 2007 and August 2010; 16 to the phase I portion and 
76 to the phase II. One of the 16 subjects in the phase I por-
tion enrolled but never received any drugs. The median age of all 
subjects was 58 y (range 20 to 83) with a median Karnofsky per-
formance status (KPS) of 90 (range 60 to 100). Other baseline 
characteristics and demographics are shown in Table 1.
Dose escalation and toxicities
In the phase I part of the study no dose-limiting toxicities 
(DLTs) were encountered at daily doses of HCQ 200 mg/d and 
HCQ 400 mg/d. At the HCQ 800 mg/d dose level, 3/3 patients 
experienced grade 4 thrombocytopenia and 2/3 patients expe-
rienced grade 4 neutropenia. One patient experienced grade 4 
neutropenia and sepsis. These toxicities occurred in all 3 subjects 
during chemoradiation. This early and severe myelosuppres-
sion (Fig. S1) was viewed as a DLT and per protocol the HCQ 
400 mg/d cohort was expanded by 3 patients; no further DLTs 
were observed. There were no DLTs in 3/3 patients at HCQ 
600 mg/d, which was therefore determined to be the MTD. 
In addition to dose-limiting myelosuppression in the HCQ 
800 mg/d dose cohort, other grade 2 toxicities common to all 
Table 1. Demographics
Characteristic RT+TMZ+HCQ phase I RT+TMZ+HCQ phase II
NABTT phase II historical
RT+Chemo
EORTC phase III
RT+TMZ
n = 16 n = 76 n = 235 n = 287
Age, y
Median 55 59 55 55
Rage 24–69 20–83 21–82 23–70
Sex, no. (%)
Male 12 (75) 46 (61) 151 (64) 151 (64)
Female 4 (25) 30 (39) 84 (36) 84 (36)
Karnofsky Performance Status, no. (%)
100 5 (31) 15 (20) 33 (18) 113 (39)
90 7 (44) 31 (41) 93 (50) 136 (47)
80 3 (19) 18 (24) 31 (17)
70 1 (6) 10 (13) 21 (11) 38 (13)
60 1 (1.3) 7 (4)
Surgical procedure no. (%)
Biopsy 6 (37) 18 (24) 29 (16) 48 (17)
Craniotomy 10 (63) 58 (76) 156 (84) 239 (83)
Histological diagnosis no. (%)
Glioblastoma 16 (100) 73 (96) 181 (98) 221 (92)
Other 3 (4) 3 (2) 18 (8)
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dose levels included nausea, fatigue, constipation, and diarrhea. 
The grades 1 to 4 toxicities that were possibly, probably or defi-
nitely associated with HCQ, TMZ, or both in the phase I study 
at each dose level are shown in Tables S1–S4. The grade 3 and 
4 toxicities with a possible, probable, or definite relationship to 
HCQ, TMZ or both in the phase II part of the trial are shown 
in Table 2.
Efficacy
As of 03/04/2013, the time of final analysis, 75 patients had 
died and 17 were living. Median onset of protocol treatment 
from initial surgery was 4.9 wk. The median time on treatment 
was 21.6 wk (range 0.1 to 91.1). The average number of adjuvant 
treatment cycles of concurrent TMZ and HCQ was 5.1. Ninety 
patients (98%) were off treatment, 66% due to disease progres-
sion or death, 3% due to toxicity, 12% due to treatment delay of 
more than 14 d, 9% due to patient refusal of further treatment, 
or 3 due to investigator withdrawal for noncompliance. The esti-
mated hazard rate was 0.59 (95% CI: 0.46 to 0.76) for the phase 
II portion of the study. The median OS was 15.6 mo (95% CI: 
13 to 17.0). For patients ages 18 to 70 y old (n = 63), median 
OS was 16.5 (95%CI: 13.0–18.0). These results are compared 
with the European Organization for Research and Treatment 
of Cancer EORTC phase III study in Table 3 and Figure S2. 
Overall, 19 of the 76 patients (25%) lived beyond 24 mo.
Pharmacodynamic and population pharmacokinetic 
analysis
To determine if autophagy inhibition was achieved in 
patients, electron microscopy (EM)-based scoring for number of 
autophagic vacuoles was conducted on serially collected periph-
eral blood mononuclear cells for any patient that had at least 
2 PBMC samples amenable to EM (40/92 patients). A mixed-
effects model revealed a significant linear trend in mean AV, 
with mean vacuole count increasing by 0.075 per wk (P = 0.041) 
in all patients (Fig. 1A). A striking accumulation of AV of vary-
ing shapes and sizes was observed in electron micrographs from a 
patient in the HCQ 800 mg/d cohort (Fig. 1B). Quantification 
of morphological parameters of AV in one patient treated in the 
800 mg HCQ cohort demonstrated a treatment-associated 9-fold 
increase in the percent of cytoplasm involved by AV, a 10-fold 
increase in AV perimeter, and a 2.5-fold increase in AV diam-
eter (Fig. S3A). Accumulation of AV and a treatment-associated 
increase in the LC3-II/LC3-I ratio indicative of an accumula-
tion of AV were present in PBMC from patients treated at lower 
nontoxic dose levels (Fig. 1C; Fig. S3B).
The population PK analysis was conducted with 262 non-
baseline blood HCQ concentration observations from 72 
patients collected over a period of up to 276 ds. The median 
number of samples per patient was 4 (range, 1 to 6). The 
population model accounted for differences in dosing sched-
ule (once vs. twice daily) and unequal doses (400 mg and 
200 mg in divided doses over the 24 h dosing interval) in the 
600 mg cohort. The population model PK parameters do not 
specifically represent steady-state values, as they were deter-
mined from multiple repeated single doses taken by individual 
patients during their period of participation in the study. To 
obtain steady-state PK parameters, individual estimates of PK 
parameters were simulated from the population model (see 
Patients and Methods). Figure 2A shows the individual pre-
dicted concentrations vs. the observed concentrations using a 
2-compartment model with first-order absorption and a lag 
time. Inter-individual variabilities for the population typi-
cal values for lag time (t
lag
), apparent oral clearance from the 
central compartment (Cl/F), inter-compartmental clearance 
(Q/F), apparent volume of distribution of the central com-
partment (V/F), apparent distribution volume of peripheral 
compartment (V2/F), and first-order absorption rate constant 
(Ka), were consistent with the published literature (Table 4). 
Individual PK parameter estimates derived from the population 
model were most variable for clearance and distribution vol-
umes (Table S5). The mean t
lag
 was 1.06 h (range, 0.97 to 1.25 
h), with mean Ka 0.51 h (range, 0.42 to 0.82), mean Ci 11.85 
L/hr (range, 6.41 to 28.18), and mean V/F 483.96 L (range, 26 
to 5483 L) with V2/F of 963 L (range, 558 to 2208 L).
Table 2. Phase ii adverse events related to study drug
Toxicity, number of patients (%) Grade 3 Grade 4 Total
abdominal pain 1 (1) 1 (1)
alanine aminotransferase increased 2 (3) 2 (3)
anemia 6 (8) 6 (8)
Blood bilirubin increased 1 (1) 1 (1)
Constipation 1 (1) 1 (1)
eye disorders 1 (1) 1 (1)
Fatigue 1 (1) 1 (1)
hemolysis 1 (1) 1 (1)
lymphocyte count decreased 6 (8) 6 (8)
Muscle weakness upper limb 1 (1) 1 (1)
neutrophil count decreased 3 (4) 8 (10) 11 (15)
Platelet count decreased 4 (5) 7 (9) 11 (15)
Pruritus 1 (1) 1 (1)
Rash maculo-papular 9 (12) 9 (12)
White blood cell decreased 7 (9) 4 (5) 11 (15)
Table 3. Overall survival
Age group Median overall 
survival, mo (95% CI)
12-mo survival 
% (95% CI)
18-mo survival 
% (95% CI)
24-mo survival 
% (95% CI)
ABTC 0603 radiation + temozolomide + hydroxychloroquine
≥ 18 (n = 76) 15.6 (13–17) 69.7 (58–80) 35.5 (25–47) 25.0 (16–36)
18–70 (n = 63) 16.5 (13–18) 74.6 (62–85) 41.3 (29–54) 30.2 (19–43)
EORTC phase III radiation + temozolomide vs. radiation alone
18–70 (n = 287) 14.6 (13–17) 61.1 (55–67) 39.4 (34–45) 26.5 (21–32)
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The range of observed individual measurements of HCQ con-
centration followed a dose-proportional relationship (Fig. 2B). 
Despite polypharmacy in this patient population, which 
included coadministration of corticosteroids, trimethoprim-
sulfamethoxazole, and anti-emetics, the HCQ concentrations 
in whole blood from groups of patients receiving the same dose 
did not show a significant time-dependent trend (Fig. S4A). 
Individual PK parameter estimates derived from the population 
analysis were used to simulate individual blood concentration vs. 
time curves, assuming a 2-compartment model with first-order 
absorption and a lag time. Simulated PK parameters for patients 
who had complete sets of PD samples (Table S5), allowed for 
investigation of the PK-PD relationship between HCQ and AV 
accumulation in PBMC.
The PK-PD relationship between HCQ and AV accu-
mulation in PBMC at 3 wk was first investigated by using an 
exploratory classification and regression trees (CART; Salford 
Predictive Modeler Builder v6.6), which iden-
tified a threshold effect of the HCQ peak 
blood concentration (Fig. 2C). The CART 
analysis was conducted using PK and PD data 
of 40 patients, with the target variable defined 
as any positive change in number of AV from 
baseline to 3 wk and C
min
, C
max
, and area 
under the curve (AUC) as predictors.
The effect of the threshold value for C
max
 
on the change in AV from baseline to 3 wk 
was then investigated using the Kruskal-
Wallis test for comparing median values and 
the Kolmogorov-Smirnov 2-sample test to 
identify any significant shift in the distribu-
tion. Patients with C
max
 below 1785 ng/mL 
(n = 22) produced a median AV change of 
-0.02 (IQR: -0.52, 0.46), while patients with 
C
max
 above 1785 ng/mL (n = 18) produced 
a median AV change of 1.01 (interquartile 
range: -0.21, 2.10) (Fig. 2D; Kruskal-Wallis 
two-sided P = 0.0342; Kolmogorov-Smirnov 
P = 0.0156). A similar PK-PD correla-
tion in PBMC at 9 wk was not significant 
(Fig. S4B).
Discussion
Autophagy is an intracellular process in 
which damaged organelles are sequestered in 
AVs. After fusion with lysosomes, the contents 
of the AV undergo acid-dependent degrada-
tion and are then recycled.12 In eukaryotic 
cells autophagy serves at least 2 functions: 1) 
as an intracellular mechanism for the disposal 
of damaged organelles and proteins, and 2) 
to catabolize substrates during cellular stress 
in order to generate energy for cell survival.13 
Therapeutic activation of stress response genes 
such as TP53/p53 (Trp53 in mouse models) can induce auto-
phagy in addition to apoptosis.14 While persistent autophagy 
by itself can result in cancer cell death, there is mounting evi-
dence that autophagy represents a key component of the damage 
response that cancer cells use to avoid death when exposed to 
metabolic and therapeutic stresses. However, when autophagy is 
inhibited, a cell that is reliant on autophagy will undergo either 
apoptotic or nonapoptotic cell death.15,16
CQ and its derivative HCQ are weak bases that are thought to 
deacidify lysosomes and thus inhibit the last step in autophagy. 
Our previous work demonstrated that autophagy inhibition 
with CQ augmented the efficacy of alkylating chemotherapy in 
a mouse tumor model.14 In patients with newly diagnosed GB, 
a previous trial of radiation and carmustine with or without 
CQ found a trend toward increased median overall survival.17 
Preclinical studies indicate that micromolar concentrations of 
CQ and its derivatives are required to inhibit autophagy.14 Since 
Figure 1. Pharmacodynamic evidence of autophagy inhibition in patients treated with temo-
zolomide (TMZ), radiation (RT), and hydroxychloroquine (hCQ). (A) Mixed-effects model of 
mean ± sD autophagic vacuoles (aVs)/cell. Dotted line: regression line. (B) Representative 
electron micrographs from a patient treated with chemoradiation and hCQ 800 mg/d for 3 wk. 
arrows, aV; scale bar: 2 µm. (C) immunoblotting against lC3 in the lysates of PBMC obtained 
from the same patient in (B). P, pretreatment; W3, 3 wk of treatment.
www.landesbioscience.com autophagy 1363
low-dose CQ prescribed for malaria prophylaxis achieves low 
nanomolar blood concentrations, dose escalation would likely be 
necessary to achieve effective autophagy inhibition in a clinical 
setting.8 As studies demonstrate that CQ and HCQ are equi-
potent autophagy inhibitors, and based on its safer toxicity pro-
file, we chose HCQ for a dose-escalation study.18,19 We cannot, 
however, exclude the possibility that TMZ, RT, and CQ would 
have proven to be a more active combination.
Surprisingly, the dose escalation in this study generated 
dose-limiting myelosuppression at HCQ 800 mg daily in com-
bination with concomitant low-dose continuous TMZ and 
RT. All 3 patients treated at this dose experienced early, severe 
Figure 2. Population pharmacokinetic-pharmacodynamic analysis. (A) individual predicted hCQ whole blood concentrations vs. observed concentra-
tions using a 2-compartment population pharmacokinetic model. (B) Observed hCQ concentrations in whole blood by dose cohort. (C) CaRT analysis. 
(D) Median aV change in patients with estimated hCQ Cmax above or below 1785 ng/ml.
Table 4. hydroxychloroquine population pharmacokinetic parameter estimates
Parameter Model estimate Bootstrap estimate CV% 2.5% CI 97.5% CI
tlag (h) 1.06 0.95 38.7 0.04 1.34
Ka (h-1) 0.49 0.05 54.5 0.43 1.06
V/F (l) 361.28 256.27 60.7 20.34 590.48
V2/F (l) 947.26 1078.94 22.0 640.30 1563.76
Cl/F (l/h) 11.44 11.39 3.9 10.54 12.31
Q (l/h) 103.9 192.65 180.5 59.86 802.21
stdev0 0.205 0.203 8.0 0.171 0.236
tlag, lag time; Ka, first-order absorption rate constant; V/F, apparent volume of distribution of central compartment; V2/F, apparent volume of 
distribution of peripheral compartment; Cl/F, apparent oral clearance; Q, intercompartmental clearance; stdev0, standard deviation; Ci, confi-
dence interval; l, liters; h, hours.
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and sustained neutropenia and/or thrombocytopenia that were 
incompatible with further treatment on protocol. While it is pos-
sible that this is a reflection of TMZ-induced myelosuppression 
that can occur during chemoradiation,20 it is in striking contrast 
to other clinical trials involving HCQ such as a phase I trial 
of TMZ (150 mg/m2 po daily 7 d on/7 d off) in combination 
with 1200 mg daily HCQ, in which no myelosuppression was 
observed (Rangwala et al., this issue24). Other HCQ combina-
tion trials also reached HCQ 1200 mg/d dosing (Vogl et al., this 
issue25; Rangwala et al., this issue26). This suggests that continu-
ous dosing of TMZ or the combination of both during chemo-
radiation produce more sustained autophagy than intermittent 
TMZ in the hematopoietic compartment and therefore sensitizes 
these host cells to HCQ-induced cytotoxicity. If so, these results 
demonstrate that the cytotoxic regimen that is paired with auto-
phagy inhibitors can produce significant variability in toxicity, 
and also raise concern over an increasingly common practice of 
adding high doses of HCQ to various cytotoxic cancer regimens 
outside the context of a clinical trial. The considerable variability 
in HCQ pharmacokinetics underscores the importance of test-
ing this approach in clinical trials.
The observed concentrations of HCQ in glioma patients in 
this study were consistent with those reported for the same doses 
given to patients with rheumatoid arthritis.21 The population PK 
model developed for our PK-PD analysis was necessitated by the 
PK properties of HCQ and the outpatient visit schedule of adju-
vant therapy for GB patients. Although the pharmacokinetics 
of HCQ have been represented by 1-, 2-, and 3-compartment 
models, our data supported a 2-compartment model, due to 
the greatest number of samples having been obtained near the 
beginning and end of the dosing interval.21-23 As with previous 
studies of HCQ pharmacokinetics, there was wide inter-and 
intra-patient variability. Unlike other investigators who have 
fixed Ka and t
lag
 to published values, we chose to estimate these 
parameters because the disposition of HCQ in patients with 
advanced cancer has not been reported, nor have the effects of 
polypharmacy and gastrointestinal side effects been described. 
These estimates may have influenced the accuracy of V/F, which 
showed considerable variability. The population PK parameters 
indicated that similar to rheumatoid arthritis patients taking 
only single-agent HCQ, GB patients taking HCQ in combina-
tion with TMZ and radiation, and the many supportive care 
medications, demonstrated dose-proportional and sustained 
exposure to HCQ.
Our finding that patients with higher C
max
 and AUC were 
more likely to demonstrate significant therapy-associated accu-
mulation of AV in PBMC is the first demonstration that auto-
phagy inhibition with HCQ can be achieved in humans. The 
major limitation of this study is that PBMC cannot fully reflect 
the complexity of autophagy dynamics that are within the tumor 
microenvironment. We chose PBMC in this study since serial 
biopsies of tumor tissue are not feasible in the GB population. 
Other HCQ studies involving malignancies with more accessible 
tumors such as multiple myeloma and melanoma have incorpo-
rated serial tumor biopsies that can be compared with PBMC to 
determine the degree of agreement between tumor and surrogate 
tissue with regard to the EM-based assay (Rangwala, et al., this 
issue26; Vogl et al., this issue25; Mahalingam et al., this issue27). 
The current study demonstrates the feasibility of incorporat-
ing the EM-based PD assay into clinical trials, and the results 
suggest that this assay can be used to guide development of 
other novel autophagy inhibitors. These data also indicate that 
at HCQ 600 mg/d in combination with TMZ and RT, many 
patients may not be achieving adequate autophagy inhibition, 
and therefore the efficacy of the phase II trial of this regimen 
as measured by prolonged overall survival may be blunted by 
inconsistent autophagy inhibition by HCQ. Given the tolerabil-
ity of higher doses of HCQ in combination with intermittent 
temozolomide (Rangwala et al., this issue24), more consistent 
and a greater degree of autophagy could likely be achievable in 
this patient population, if the HCQ dose were maintained at 
600 mg/d for the first 6 wk of chemoradiation and then dose-
escalated during adjuvant temozolomide. Another approach to 
consider for future trials is to incorporate an intermittent dose-
intense temozolomide and HCQ regimen (as used in Rangwala 
et al., this issue24) in combination with brain radiation so that 
higher doses of HCQ might be achieved early in the course of 
GB therapy. Alternatively, the role of autophagy as a targetable 
resistance mechanism in front-line GB may best be answered by 
testing novel autophagy inhibitors that are more potent and tol-
erable than HCQ.
Patients and Methods
Study design and objectives
This was an open-label, multi-center, phase I/II trial in 
adults with newly diagnosed GB conducted by the American 
Brain Tumor Consortium (ABTC) (Clinical Trials.gov 
NCT00486603). The study was reviewed and approved by the 
National Cancer Institute and the individual institutional review 
board of each of the 10 participating institutions (University 
of Pennsylvania, Johns Hopkins University, Wake Forest 
University, H Lee Moffitt Cancer Center, Henry Ford Hospital, 
Emory University, University Hospitals Case Medical Center, 
Dana Farber Cancer Institute, Massachusetts General Hospital, 
and University of California San Francisco), and informed con-
sent was obtained from each subject. The primary objective of 
the phase I study was to determine the maximum tolerated dose 
of HCQ when administered in conjunction with RT and con-
comitant and adjuvant TMZ. Upon completion of the phase 
I trial, patients were enrolled to a single-arm phase II trial and 
treated with MTD of HCQ in combination with RT and TMZ. 
The primary objective of the phase II cohort was overall survival. 
The secondary objectives of this trial were to a) characterize the 
population PK profile of HCQ; b) determine if PD evidence of 
autophagy inhibition could be detected in PBMC; and c) corre-
late PK with PD findings to determine the relationship between 
HCQ exposure and autophagy inhibition.
Eligibility criteria
Patients ≥ 18 y of age with histologically confirmed supraten-
torial GB diagnosed < 3 mo prior to registration were eligible. 
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Other criteria included no prior tumor-directed therapy other 
than surgery, KPS ≥ 60%, normal hematological, adequate 
renal and liver function (transaminases ≤ 4 times the upper 
limits of the institutional normal), ability to provide written 
informed consent, and Mini Mental State Exam score of ≥ 15. 
Exclusion criteria included pregnancy or breast feeding, car-
mustine (Gliadel®) wafers, or a history of macular degeneration, 
diabetic retinopathy, porphyria, or psoriasis. Patients requiring 
cytochrome P450 enzyme-inducing anticonvulsant drugs were 
not eligible.
Treatment plan
Commencement of protocol therapy began as soon as medi-
cally appropriate, but, no later than 3 mo after craniotomy. All 
subjects received conventional external beam RT as utilized 
by the Radiation Therapy Oncology Group. This consisted of 
60 Gy in 30 fractions delivered with megavoltage machines. 
The initial target treatment volume was defined as the contrast-
enhancing lesion plus edema plus a 1 cm margin. The cone-
down target volume included the enhancing lesion plus a 1.0 cm 
margin. Electron, particle, implant, or stereotactic radiosurgery 
boosts were not allowed. Prophylaxis for pneumocystis jirovecii 
was mandatory during RT.
Daily oral TMZ (75 mg/m2; Merck) was administered 1 h 
before each RT session or in the AM on ds without RT. Dose 
delays or discontinuation occurred for hematological and non-
hematological toxicity; once resolved, TMZ was resumed 
without making up lost doses. Dose reductions were not 
allowed during RT. The 6 wk of RT and TMZ (chemoradia-
tion) plus a 4-wk rest period was considered the initiation cycle. 
Maintenance cycles began after the initiation cycle and consisted 
of TMZ at a dose of 150 mg/m2/d for 5 consecutive d every mo 
for 6 mo (escalated in subsequent cycles to 200 mg/m2 in the 
absence of toxicity).
HCQ (obtained by patients through prescriptions at retail 
pharmacies, and manufactured by numerous generic pharma-
ceutical manufacturers) administration began on the first d of 
chemoradiation and continued daily without any planned inter-
ruptions including during the 4-wk rest period. Upon comple-
tion of 6 maintenance cycles of TMZ + HCQ patients continued 
with daily HCQ alone in monthly cycles with no limit to the 
number of cycles.
Dose escalation and definition of maximal tolerated dose
The planned daily doses for HCQ were 200 mg, 400 mg 
(given as 200 mg twice a day) and 800 mg (given as 400 mg 
twice a day). After toxicity was observed at 800 mg daily the 
protocol was amended to include a cohort at 600 mg HCQ daily 
(given as 400 mg in the morning and 200 mg in the evening). 
Three patients were treated per dose level. Before accrual to the 
next dose level began, all patients in a given cohort completed the 
10-wk initiation cycle, permitting toxicities to be assessed (DLT 
period). No dose escalation beyond 800 mg/d was planned.
Treatment-related DLT was defined as any non-hemato-
logical grade 3 and 4 toxicities possibly, probably, or definitely 
HCQ-related (except nausea and vomiting without sufficient 
antiemetic prophylaxis). Known or reasonably suspected TMZ 
hematological toxicities were not considered dose-limiting unless 
the toxicity was felt to be significantly exacerbated by HCQ. 
Any adverse effect (AE) of ≥ grade 3 attributed to HCQ (nau-
sea, vomiting, diarrhea, rash, and visual field deficit) resulted in 
the dose being held until the AE had resolved to ≤ grade 1 or 
baseline. If the AE resolved, reinstitution of treatment occurred 
at a dose reduced by 200 mg daily with up to 3 dose reduc-
tions allowed for subsequent toxicity. During maintenance 
cycles TMZ dosing was reduced if platelets < 50 × 109/L and/
or absolute neutrophil count < 1 × 109/L, by increments of 
50 mg/m2, with 100 mg/m2 the lowest allowed treatment dose 
for continuation on study. Adverse events and toxicities were 
graded according to Common Terminology Criteria for Adverse 
Events version 3.0.
Patient evaluation
Evaluations performed within 14 d of beginning therapy 
included a medical history, physical and neurological exami-
nations, Mini-Mental Status Exam, KPS determination, elec-
trocardiogram, chest radiograph, vital signs, blood count with 
differential and platelet counts (complete blood count), blood 
coagulation parameters, serum chemistry profile, urinalysis, and 
pregnancy test for women of child-bearing potential. During the 
initiation cycle a complete blood count was performed weekly 
or more often if grade 3 or 4 myelosuppression was observed. 
History, physical and neurological examinations, Mini-metal 
status exam, KPS determination, complete blood count, and 
serum chemistries were performed within 3 d before every main-
tenance cycle.
Imaging studies were performed within 14 d of beginning 
treatment and after every 2 maintenance cycles (of HCQ and 
TMZ or HCQ alone). If criteria for progression (new lesions on 
imaging, or neurologic deterioration on stable or increasing cor-
ticosteroids without another explanation) were met, the patient 
would be removed from study. In the absence of progression, 
treatment with TMZ and HCQ was continued for a maximum 
of 6 maintenance cycles. This was followed by monthly cycles 
of HCQ alone until progression or removal from study for other 
reasons.
Statistical considerations and data analyses
The conventional 3 + 3 design with 4 pre-specified dose levels 
was used in the phase I portion of the study with a target DLT 
rate of ≤ 33%. The MTD was defined as (a) the dose produc-
ing DLT in 2 out of 6 patients, or (b) the dose level below the 
dose which produced DLT in ≥ 2 out of 3 patients, or in ≥ 3 
out of 6 patients. No intra-patient dose escalation was permitted. 
Patients were evaluable for the cohort if they completed 90% of 
their expected dose of HCQ for the initiation cycle. Patients who 
experienced a DLT were evaluable for the cohort after at least 
one dose of HCQ.
For assessing the efficacy of the regimen in term of overall 
survival in the phase II portion of the study, the overall fail-
ure rate was estimated and compared with the failure rate of 
0.6 per person-year of follow-up found in a phase III trial per-
formed in the same patient population treated with RT plus 
concomitant and adjuvant TMZ.1 The primary endpoint was 
death due to any cause and survival time was defined from 
time of histological diagnosis to death. The overall failure rate 
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was expressed as hazard of failure per person-year of follow-up. 
The trial was designed to have 90% power to detect a hazard 
ratio of 0.70, a 30% reduction in hazard rate of death from a 
hazard rate of 0.6 in the phase III trial at an α level of 0.1 (one-
sided). A minimum of 55 death events was required at the time 
of analysis. Central review of pathology and neuroimaging was 
mandated for all patients with a documented complete or par-
tial response. Survival probability and median time of survival 
were calculated using the Kaplan-Meier method. All P values 
reported are 2-sided unless specified. All analyses were per-
formed with SAS software (version 9.2; SAS Institute). For PD 
analysis of AV a mixed-effects model was fit to the mean auto-
phagic vacuoles for all patients (n = 40) and phase II patients 
only (n = 20). The model included a fixed effect of continuous 
measurement time (baseline, week 3, week 9) and a random 
subject effect.
Pharmacodynamic assessment of autophagy
Sixteen milliliters of venous blood was collected in BD CPT 
vacutainer tubes (BD, Inc., 37253) from patients prior to treat-
ment, 3 wk after starting protocol therapy (during chemora-
diation and HCQ) and 9 wk after starting treatment (while 
receiving HCQ alone). Manufacturer’s instructions were fol-
lowed to collect PBMC in 2 cell pellets. Cells obtained from 
PBMC pellet one were immediately fixed with 2% glutaralde-
hyde and stored at 4 °C until embedding. Embedding and image 
capture were performed as previously described.14 For quantifi-
cation of AV in PBMC using electron microscopy, high-pow-
ered micrographs (10,000–12,000×) of 20 to 25 mononuclear 
cells from multiple distinct low-powered fields in each sample 
were obtained. Autophagic vacuoles were scored by 2 indepen-
dent investigators who were blinded to treatment time points. 
Morphological criteria for AV included 1) circularity, 2) contrast 
with structures that were white or lighter than the cytoplasm, 
3) vacuoles with contents, 4) vacuoles > 200 nm in size and, 
5) vacuoles > 200 nm interior to the plasma membrane. Vesicular 
structures with cristae characteristic of mitochondria in cross sec-
tion were excluded. The average of 2 investigators counts are pre-
sented as mean ± standard error of the mean. PBMC pellet 2 was 
immediately frozen. For immunoblotting, after thawing on ice, 
the pellet was lysed with RIPA buffer (prepared according to ref. 
14). Protein from cell lysates were resolved by gel electrophore-
sis and transferred to nitrocellulose membrane. Immunoblotting 
was performed using anti-MAP1LC3B (LC3, 1:500; QCB 
Biologicals, antibodies raised in rabbits using rat LC3B N ter-
minus peptide) and anti-ACTB (actin, 1:5000; Sigma, A1978) 
antibodies as previously described.14
Pharmacokinetic analysis of HCQ
Collection of PK samples
Whole blood was collected from each patient at the following 
time points: 1) within 14 d prior to starting protocol therapy 
(baseline); 2) wk 3–4; 3) wk 9–10; wk 4 of maintenance cycles 
1, 2, 3, and 6. Blood was collected in green top tubes contain-
ing sodium heparin (BD, 367884), and stored at ≤ 70 °C until 
analysis. Pharmacokinetic logs were maintained to document 
the timing of last meal and most recent HCQ ingestion, timing 
of blood draw, and concurrent medications.
Determination of HCQ in blood
Study samples were thawed at room temperature and mixed 
before removing a 100-µL aliquot for analysis. After spiking 
with 5 µL of internal standard (IS) working solution (10 µg/mL 
chloroquine [Sigma-Aldrich, C6628] in acetonitrile), the sample 
was vigorously mixed with 300 µL of acetonitrile, then centri-
fuged (10,000 g, 5 min). The supernatant fraction (250 µL) was 
combined with 200 mM triethylamine (Sigma-Aldrich, T0886), 
272 mM formic acid (Sigma-Aldrich, F0507) in water (25 µL) 
and 100 µL of this solution was injected onto a 150 × 4.6 mm 
Luna 5 µm CN HPLC column (Phenomenex, Torrance, CA) 
eluted with a binary mobile phase composed of 30% acetonitrile 
(Sigma-Aldrich, 271004) and 70% 10 mM triethylamine, 13.6 
mM formic acid in water (pH 4.0) delivered at 1.0 mL/min. An 
Agilent 1100 Series LC/MSD system with an electrospray ioniza-
tion interface (Agilent Technologies, Palo Alto, CA) was used for 
detection. Nitrogen was used as the nebulizing gas (60 p.s.i.) and 
as the drying gas (10 L/min, 350 °C). The single-quadrupole mass 
spectrometer was operated in the selected ion-monitoring mode 
to measure positive ions corresponding to [M + H]+ ions of HCQ 
and the IS at m/z 336.2 and 320.2, respectively. Additional oper-
ating parameters were: capillary voltage, 1,500 V; fragmentor volt-
age, 150 V; peak width, 0.1 min; dwell time, 114 msec. Extracted 
ion chromatograms were integrated to provide peak areas.
Calibration standards of HCQ in human whole blood had 
concentrations ranging from 10 to 1,000 ng/mL. Study sam-
ples were independently assayed in duplicate, on different ds, 
together with a set of calibration standards, drug-free blood pre-
pared for analysis with and without addition of the IS, and a set 
of 3 quality control samples (HCQ 30, 450, and 900 ng/mL in 
whole blood). The calibration curves were best described by the 
equation, y = a + bxc, where y is the HCQ/IS peak area ratio and 
x is the known analyte concentration in each calibration stan-
dard. Nonlinear regression was performed using WinNonlin 
Professional version 5.0 software (Pharsight Corp., Cary, NC), 
with weighting in proportion to the reciprocal of the HCQ con-
centration, normalized to the number of calibration standards, 
to determine the y-intercept (a), coefficient (b) and exponent 
(c), of the best-fit curve. Values of the parameters describing the 
best-fit line were used to calculate the analyte concentration in 
study samples. Specimens with concentrations exceeding the 
upper range of the standard curve were reassayed upon appropri-
ate dilution with drug-free human plasma or whole blood. The 
average of the 2 initial determinations of each study sample was 
calculated. Samples were reassayed in cases where the individual 
determinations differed from their average by more than 15%. 
During the analysis of samples from this study, the calibration 
curves exhibited correlation coefficients ranging from 0.995 to 
1.000 and the inter-d accuracy was within ± 8% of the known 
concentration of the calibration standards and quality-control 
solutions with a precision ≤ 4.2%.
Population PK modeling
Initial estimates for a base population model were derived 
from a naïve-pooled data analysis of individual patient blood 
concentration time data. One and 2-compartment models with 
first-order absorption and elimination, with and without a lag 
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time, were evaluated as the potential pharmacokinetic structural 
model. Visual inspection of conditional weighted residuals vs. 
individual predicted values plots suggested that a multiplicative 
error model was appropriate, Diagnostic scatter plots and Akaike 
information criteria were used to select the base model, a 2-com-
partment model with a lag-time variable.
Visual inspections of scatter and box plots for eta (random 
effect) values were used to explore potential continuous (age, 
weight, KPS, minimental exam log weight, log age) and cat-
egorical (corticosteroid use, anticonvulsant use, sex) covariates. 
Covariates were centered on their median values. Stepwise covari-
ate selection processes were conducted to build the full model. 
Model building criteria were based on covariate models associ-
ated with an increase in objection function value greater than 
3.84 with 1 degree of freedom (P < 0.05) using the likelihood 
ratio test. No covariant interactions significantly improved the 
model. The first order with conditional estimates extended least 
squares method was used to confirm the final model, which was 
as follows: Cl/f = tvCl/F * exp(nCl)/F; Q = tvQ * exp(nQ); V/F 
= tvV/F * exp(nV)/F; V2/F = tvV2/F * exp(nV2)/F; Ka = tvKa 
* exp(nKa), t
lag
 = tvt
lag
 * exp(nt
lag
). The predictive ability of the 
final model was evaluated using a Monte Carlo simulation with 
200 simulated data sets based on the parameters and time points. 
Bootstrapping with 1000 subjects per each bootstrap run was 
conducted to provide estimates of the precision of fixed effects.
Individual pharmacokinetic parameters (Cl/F, Q, V/F, V2/F, 
Ka, t
lag
) for each patient were derived from the final population 
model and used to simulate time-concentration profiles using 
a one-compartment model with WinNonlin® 6.2 (Pharsight 
Corporation, Cary, NC). The simulated blood HCQ concentra-
tions were compared with observed concentrations to determine 
the predictive performance of the model. HCQ pharmacokinetic 
parameter estimates (peak blood concentration, C
max
; area under 
the concentration-vs.-time curve, AUC) from these simulations 
were used to explore pharmacokinetic-pharmacodynamic (PK-
PD) relationships.
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